Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.87 USD
+1.07 (22.29%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $5.78 -0.09 (-1.53%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FHTX 5.87 +1.07(22.29%)
Will FHTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for FHTX
Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability
Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
Foghorn Therapeutics Unveils Strategic Plans to Investors
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June